JP2024518410A5 - - Google Patents
Info
- Publication number
- JP2024518410A5 JP2024518410A5 JP2023568333A JP2023568333A JP2024518410A5 JP 2024518410 A5 JP2024518410 A5 JP 2024518410A5 JP 2023568333 A JP2023568333 A JP 2023568333A JP 2023568333 A JP2023568333 A JP 2023568333A JP 2024518410 A5 JP2024518410 A5 JP 2024518410A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- dose
- pharmaceutical product
- approximately
- product according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163185613P | 2021-05-07 | 2021-05-07 | |
| US63/185,613 | 2021-05-07 | ||
| US202263303655P | 2022-01-27 | 2022-01-27 | |
| US63/303,655 | 2022-01-27 | ||
| PCT/US2022/028063 WO2022236047A1 (en) | 2021-05-07 | 2022-05-06 | Use of an anti-cd19 antibody to treat myasthenia gravis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024518410A JP2024518410A (ja) | 2024-05-01 |
| JP2024518410A5 true JP2024518410A5 (enExample) | 2025-05-13 |
Family
ID=81846343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023568333A Pending JP2024518410A (ja) | 2021-05-07 | 2022-05-06 | 重症筋無力症を治療するための抗ｃｄ１９抗体の使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240270842A1 (enExample) |
| EP (1) | EP4333987A1 (enExample) |
| JP (1) | JP2024518410A (enExample) |
| KR (1) | KR20240004367A (enExample) |
| AU (1) | AU2022270697A1 (enExample) |
| BR (1) | BR112023022133A2 (enExample) |
| CA (1) | CA3217586A1 (enExample) |
| IL (1) | IL308296A (enExample) |
| MX (1) | MX2023012703A (enExample) |
| WO (1) | WO2022236047A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024155810A1 (en) * | 2023-01-20 | 2024-07-25 | Viela Bio, Inc. | Anti-cd19 binding agents for the treatment and prevention of immune mediated necrotizing myopathy |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69303494T2 (de) | 1992-11-13 | 1997-01-16 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma |
| AU3272695A (en) | 1994-08-12 | 1996-03-07 | Immunomedics Inc. | Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells |
| AU2001268427B2 (en) | 2000-06-16 | 2007-03-29 | Glaxosmithkline Intellectual Property Limited | Antibodies that immunospecifically bind to blys |
| EA010594B1 (ru) | 2001-05-24 | 2008-10-30 | Займодженетикс, Инк. | Слитые белки taci-иммуноглобулина |
| KR20110017020A (ko) | 2002-10-17 | 2011-02-18 | 젠맵 에이/에스 | Ｃｄ20에 대한 인간 모노클로날 항체 |
| EP1944320A1 (en) | 2002-12-16 | 2008-07-16 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| PT2272868E (pt) | 2003-06-05 | 2015-07-07 | Genentech Inc | Terapêutica de combinação para distúrbios de células b |
| DOP2006000029A (es) | 2005-02-07 | 2006-08-15 | Genentech Inc | Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas) |
| JP5401314B2 (ja) | 2006-09-08 | 2014-01-29 | メディミューン，エルエルシー | ヒト化抗ｃｄ１９抗体ならびに癌、移植および自己免疫疾患の治療におけるその使用 |
| WO2009052431A2 (en) * | 2007-10-19 | 2009-04-23 | Seattle Genetics, Inc. | Cd19 binding agents and uses thereof |
| JP2012518404A (ja) * | 2009-02-23 | 2012-08-16 | グレンマーク・ファーマシューティカルズ・エスエー | Ｃｄ１９に結合するヒト化抗体及びその使用 |
| EP3157553A4 (en) | 2014-06-16 | 2018-02-28 | Xencor, Inc. | Treatment for chronic lymphocytic leukemia (cll) |
| JP2019515874A (ja) | 2016-03-01 | 2019-06-13 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 改変された細胞死誘導を有するオビヌツズマブ変異体 |
| CN113939532A (zh) * | 2019-04-24 | 2022-01-14 | 维埃拉生物股份有限公司 | 使用抗cd19抗体治疗自身免疫性疾病 |
-
2022
- 2022-05-06 CA CA3217586A patent/CA3217586A1/en active Pending
- 2022-05-06 EP EP22725660.9A patent/EP4333987A1/en active Pending
- 2022-05-06 MX MX2023012703A patent/MX2023012703A/es unknown
- 2022-05-06 IL IL308296A patent/IL308296A/en unknown
- 2022-05-06 KR KR1020237036834A patent/KR20240004367A/ko active Pending
- 2022-05-06 US US18/559,195 patent/US20240270842A1/en active Pending
- 2022-05-06 JP JP2023568333A patent/JP2024518410A/ja active Pending
- 2022-05-06 WO PCT/US2022/028063 patent/WO2022236047A1/en not_active Ceased
- 2022-05-06 AU AU2022270697A patent/AU2022270697A1/en active Pending
- 2022-05-06 BR BR112023022133A patent/BR112023022133A2/pt unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sabatelli et al. | Pure motor chronic inflammatory demyelinating polyneuropathy | |
| JP6250728B2 (ja) | α−２Ｂアドレナリン受容体作動薬を用いて制御性Ｔ細胞を活性化する方法 | |
| JP7564347B2 (ja) | 多発性硬化症を治療するためのｌｏｕ０６４ | |
| JP2025507678A5 (enExample) | ||
| US20210163955A1 (en) | Endomucin inhibitor as an anti-angiogenic agent | |
| Wroblewski et al. | Long-term daclizumab therapy for the treatment of noninfectious ocular inflammatory disease | |
| Rommer et al. | Repurposing multiple sclerosis drugs: a review of studies in neurological and psychiatric conditions | |
| TW202342099A (zh) | 醫藥組合物 | |
| JP2023536944A (ja) | 疾患の治療におけるｂｔｋ阻害剤の使用 | |
| Nowak et al. | The position of monoclonal antibodies and small molecules in the treatment of thyroid orbitopathy | |
| JP7186214B2 (ja) | 自己免疫性神経筋疾患を処置するためのクラドリビンの使用 | |
| Giesser | Multiple sclerosis: current concepts in management | |
| Zanon-Moreno et al. | New horizons for the treatment of glaucoma. I: Neuroinflammation and inflammasomes | |
| US20170035735A1 (en) | Use Of Enoximone In The Treatment Of Atopic Immune-Related Disorders, In Pharmaceutical Composition As Well As In Pharmaceutical Preparation | |
| US20240270842A1 (en) | Use of an anti-cd19 antibody to treat myasthenia gravis | |
| Ugradar et al. | The Use of Biologics for Thyroid Eye Disease: S. Ugradar et al. | |
| US20210322422A1 (en) | Use of akt inhibitors in ophthalmology | |
| Pazzola et al. | Biologics in vasculitides: Where do we stand, where do we go from now? | |
| KR20180050410A (ko) | 항-CD20 및 항-BLyS 항체의 조합물의 투여양생법 | |
| Gul et al. | Safe, Rapid-Onset, and Sustained Biological Activity of IL-1beta Regulating Antibody XOMA 052 in Resistant Uveitis of Behçet’s Disease: Preliminary Results of a Pilot Trial | |
| Khim | Myasthenia gravis treatment | |
| Yadav et al. | Novel drug delivery system in the management of myasthenia gravis | |
| Akkus et al. | Recent treatment guidelines and approach toward autoimmune encephalitis | |
| Hasiri et al. | Intra-vitreal injection of methotrexate in experimental endotoxin-induced uveitis in rabbit | |
| Sullivan et al. | Emerging therapeutic strategies for asthma management |